Browse GRIN2B

Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Cell junction, synapse, postsynaptic cell membrane Multi-pass membrane protein
Domain PF01094 Receptor family ligand binding region
PF00060 Ligand-gated ion channel
PF10613 Ligated ion channel L-glutamate- and glycine-binding site
PF10565 N-methyl D-aspartate receptor 2B3 C-terminus
Function

Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) (PubMed:8768735, PubMed:26919761, PubMed:26875626, PubMed:28126851). Sensitivity to glutamate and channel kinetics depend on the subunit composition (PubMed:8768735, PubMed:26875626). In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death. Contributes to neural pattern formation in the developing brain. Plays a role in long-term depression (LTD) of hippocampus membrane currents and in synaptic plasticity (By similarity).

> Gene Ontology
 
Biological Process GO:0007215 glutamate receptor signaling pathway
GO:0007611 learning or memory
GO:0035235 ionotropic glutamate receptor signaling pathway
GO:0044708 single-organism behavior
GO:0045471 response to ethanol
GO:0048013 ephrin receptor signaling pathway
GO:0050890 cognition
GO:0097305 response to alcohol
Molecular Function GO:0004970 ionotropic glutamate receptor activity
GO:0004972 NMDA glutamate receptor activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005216 ion channel activity
GO:0005230 extracellular ligand-gated ion channel activity
GO:0005231 excitatory extracellular ligand-gated ion channel activity
GO:0005234 extracellular-glutamate-gated ion channel activity
GO:0008066 glutamate receptor activity
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0016594 glycine binding
GO:0016597 amino acid binding
GO:0022803 passive transmembrane transporter activity
GO:0022824 transmitter-gated ion channel activity
GO:0022834 ligand-gated channel activity
GO:0022835 transmitter-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0030594 neurotransmitter receptor activity
GO:0031406 carboxylic acid binding
GO:0043168 anion binding
Cellular Component GO:0008328 ionotropic glutamate receptor complex
GO:0017146 NMDA selective glutamate receptor complex
GO:0034702 ion channel complex
GO:0043235 receptor complex
GO:0045211 postsynaptic membrane
GO:0097060 synaptic membrane
GO:0098794 postsynapse
GO:0098802 plasma membrane receptor complex
GO:0098878 neurotransmitter receptor complex
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04024 cAMP signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
hsa04713 Circadian entrainment
hsa04720 Long-term potentiation
hsa04724 Glutamatergic synapse
hsa04728 Dopaminergic synapse
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-442755: Activation of NMDA receptor upon glutamate binding and postsynaptic events
R-HSA-422475: Axon guidance
R-HSA-442729: CREB phosphorylation through the activation of CaMKII
R-HSA-442742: CREB phosphorylation through the activation of Ras
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928662: EPHB-mediated forward signaling
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-6794361: Interactions of neurexins and neuroligins at synapses
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-438064: Post NMDA receptor activation events
R-HSA-169893: Prolonged ERK activation events
R-HSA-6794362: Protein-protein interactions at synapses
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-442982: Ras activation uopn Ca2+ infux through NMDA receptor
R-HSA-8849932: SALM protein interactions at the synapses
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-438066: Unblocking of NMDA receptor, glutamate binding and activation
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GRIN2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GRIN2B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GRIN2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.3750.0293
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.8570.204
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.780.607
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2180.783
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-10.517
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4880.751
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0760.849
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0760.901
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2240.536
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GRIN2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.4021.40.081
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103300300.528
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.86.880.247
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.88.56.30.453
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211742.911.831.10.07
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131161.518.243.30.0472
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382718.43.714.70.126
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614250250.103
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GRIN2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GRIN2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GRIN2B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GRIN2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GRIN2B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GRIN2B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGRIN2B
Nameglutamate receptor, ionotropic, N-methyl D-aspartate 2B
Aliases GluN2B; NMDAR2B; EIEE27; MRD6; NR2B; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate re ......
Chromosomal Location12p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GRIN2B collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GRIN2B.
ID Name Drug Type Targets #Targets
DB00142Glutamic AcidSmall MoleculeAADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, CPQ, DNPEP ......69
DB00289AtomoxetineSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC ......10
DB00312PentobarbitalSmall MoleculeCHRNA4, CHRNA7, GABRA1, GABRA1, GABRA2, GABRA2, GABRA3, GABRA3, GA ......34
DB00418SecobarbitalSmall MoleculeCHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GR ......17
DB00454PethidineSmall MoleculeCES1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, GRIN1, GRIN2A, GRIN2B, GR ......16
DB00502HaloperidolSmall MoleculeDRD1, DRD2, DRD3, GRIN2B, HTR2A, MCHR1, SLC18A27
DB00659AcamprosateSmall MoleculeGABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GA ......24
DB00949FelbamateSmall MoleculeGRIN2A, GRIN2B, GRIN3A3
DB00996GabapentinSmall MoleculeADORA1, CACNA1B, CACNA2D1, CACNA2D2, GABBR1, GABBR2, GRIN1, GRIN2A ......13
DB01043MemantineSmall MoleculeDRD2, GRIN1, GRIN2A, GRIN2B, GRIN3A, HTR3A6
DB01174PhenobarbitalSmall MoleculeCHRNA4, CHRNA7, GABRA1, GRIA2, GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN2 ......13
DB01520TenocyclidineSmall MoleculeGRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B6
DB01708PrasteroneSmall MoleculeAR, ESR1, ESR2, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GA ......33
DB01956TaurineSmall MoleculeGABBR1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GA ......21
DB04896MilnacipranSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC ......9
DB05956EVT-101Small MoleculeGRIN2B, RXRA2
DB06151AcetylcysteineSmall MoleculeACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, SLC ......10
DB06738KetobemidoneSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, OPRD1, OPRK ......10
DB06741GavestinelSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B7
DB08954IfenprodilSmall MoleculeGRIN1, GRIN2B2
DB09409Magnesium acetate tetrahydrateSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B7
DB09481Magnesium carbonateSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B7
DB13146Fluciclovine (18F)Small MoleculeGRIA1, GRIA2, GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, ......14